2. Search Result
Search Result
Results for "

KATP+channel

" in MedChemExpress (MCE) Product Catalog:

65

Inhibitors & Agonists

1

Biochemical Assay Reagents

1

Peptides

8

Natural
Products

11

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0112
    Minoxidil
    Maximum Cited Publications
    11 Publications Verification

    U10858

    		 Potassium Channel Endogenous Metabolite Cardiovascular Disease Cancer
    Minoxidil (U10858) is an ATP-sensitive potassium (KATP) channel opener, a potent oral antihypertensive agent and a peripheral vasodilator that promotes vasodilation also affects hair growth. Minoxidil is also a potent inhibitor of soybean lipoxygenaseare with an IC50 of 20 μM .
    Minoxidil
  • HY-15589
    GW9508
    5+ Cited Publications

    		 Free Fatty Acid Receptor Potassium Channel Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    GW9508 is a potent and selective G protein-coupled receptors FFA1 (GPR40) and GPR120 agonist with pEC50s of 7.32 and 5.46, respectively. GW9508 shows ~100-fold selectivity for GPR40 over GPR120. GW9508 is inactive against other GPCRs, kinases, proteases, integrins and PPARs. GW9508 is a glucose-sensitive insulin secretagogue and an ATP-sensitive potassium (KATP) channels opener. Anti-inflammatory and anti-atherosclerotic activities .
    GW9508
  • HY-113147
    L-Palmitoylcarnitine
    2 Publications Verification

    		 Potassium Channel Endogenous Metabolite Cardiovascular Disease Metabolic Disease
    L-Palmitoylcarnitine, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine inhibits KATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2 .
    L-Palmitoylcarnitine
  • HY-N0466
    Rebaudioside A

    		Glycosidase HMG-CoA Reductase (HMGCR) Fatty Acid Synthase (FASN) LDLR Others
    Rebaudioside A is an orally effective steviol glycoside with high sweetness. Rebaudioside A acts as an inhibitor of α-glucosidase with an IC50 value of 35.01 μg/mL. Rebaudioside A increases the ATP/ADP ratio in β cells in a glucose-dependent manner, thereby inhibiting KATP channels, leading to membrane depolarization, calcium influx, and ultimately stimulating insulin secretion. Rebaudioside A activates the SREBP signaling pathway by inhibiting HMGCR, the rate-limiting enzyme in cholesterol synthesis, resulting in increased expression of LDLR on the cell surface, thus promoting the uptake of LDL-C in the blood. Rebaudioside A can be used for studies on blood glucose and lipid regulation as well as anti-obesity .
    Rebaudioside A
  • HY-113147A
    L-Palmitoylcarnitine chloride
    2 Publications Verification

    		 Potassium Channel Endogenous Metabolite Cardiovascular Disease Metabolic Disease
    L-Palmitoylcarnitine chloride, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine chloride inhibits KATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2 .
    L-Palmitoylcarnitine chloride
  • HY-136615
    5-Hydroxydecanoate sodium

    		Potassium Channel Neurological Disease
    5-Hydroxydecanoate sodium is a selective ATP-sensitive K + (KATP) channel blocker (IC50 of ~30 μM). 5-Hydroxydecanoate sodium is a substrate for mitochondrial outer membrane acyl-CoA synthetase and has antioxidant activity .
    5-Hydroxydecanoate sodium
  • HY-108575
    Chromanol 293B
    1 Publications Verification

    		 Potassium Channel CFTR Cardiovascular Disease
    Chromanol 293B is a selective blocker of the slow delayed rectifier K + current (IKs) with IC50 of 1-10 μM and a weak inhibitor of KATP channel. Chromanol 293B also blocks the CFTR chloride current with an IC50 of 19 μM .
    Chromanol 293B
  • HY-B0254
    Glipizide
    2 Publications Verification

    CP 28720; K 4024

    		 Potassium Channel Metabolic Disease Cancer
    Glipizide (CP 2872; K 4024)?a potent, orally active and sulfonylurea class anti-diabetic agent and can be used for type 2?diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium?(KATP) channels among β cells of pancreatic islets of Langerhans .
    Glipizide
  • HY-113147AS
    L-Palmitoylcarnitine-d3 hydrochloride

    		Potassium Channel Endogenous Metabolite Cardiovascular Disease Metabolic Disease
    L-Palmitoylcarnitine-d3 hydrochloride is the deuterium labeled L-Palmitoylcarnitine hydrochloride. L-Palmitoylcarnitine hydrochloride, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine hydrochloride inhibits KATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2 .
    L-Palmitoylcarnitine-d3 hydrochloride
  • HY-B0327
    Irsogladine
    3 Publications Verification

    Dicloguamine

    		 Phosphodiesterase (PDE) NF-κB AP-1 TRP Channel Interleukin Related Inflammation/Immunology Cancer
    Irsogladine (Dicloguamine) is an orally active gastric mucosal protective agent. Irsogladine inhibits breast cancer recurrence and lung metastasis in nude mice . Irsogladine inhibits the transcriptional activities of NF-κB and AP-1, suppresses the activities of PDE and PDE4 to elevate intracellular cAMP levels, and activates TRPV1 and KATP channels. Irsogladine enhances iNOS expression, NO production, and the activation of cAMP-responsive elements. Irsogladine inhibits the development and progression of intestinal polyps in Apc-mutant mice. Irsogladine alleviates oxidative stress, increases gastric mucosal blood flow, and stimulates the production of endogenous prostaglandins. Irsogladine promotes insulin secretion in MIN6 cells. Irsogladine inhibits tumor angiogenesis, cancer cell proliferation, and the production of proinflammatory cytokines. Irsogladine exerts protective effects on astrocytes in ethanol/hydrochloric acid-induced gastric ulcers in mice. Irsogladine prevents colitis in IL-10 gene-deficient mice by reducing the production of IL-12 and IL-23. Irsogladine upregulates gap junction intercellular communication in pancreatic cancer cells via the PKA pathway. Irsogladine is applicable to research related to breast cancer, intestinal polyposis, gastric ulcer, spontaneous colitis, glioma, liver cancer, and pancreatic cancer [5][6] .
    Irsogladine
  • HY-B0682A
    Mitiglinide calcium hydrate
    2 Publications Verification

    KAD-1229; S-21403

    		 Potassium Channel Metabolic Disease
    Mitiglinide calcium hydrate (KAD-1229), an insulinotropic agent, is an ATP-sensitive K + (KATP) channel antagonist. Mitiglinide calcium hydrate is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium hydrate can be used for the research of type 2 diabetes .
    Mitiglinide calcium hydrate
  • HY-17398
    Mitiglinide calcium
    2 Publications Verification

    KAD-1229 anhydrous; S21403 anhydrous

    		 Potassium Channel Metabolic Disease
    Mitiglinide Calcium (KAD-1229 anhydrous), an insulinotropic agent, is an ATP-sensitive K + (KATP) channel antagonist. Mitiglinide Calcium is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium can be used for the research of type 2 diabetes .
    Mitiglinide calcium
  • HY-B0112R
    Minoxidil (Standard)

    U10858 (Standard)

    		 Reference Standards Potassium Channel Endogenous Metabolite Cardiovascular Disease Cancer
    Minoxidil (Standard) is the analytical standard of Minoxidil. This product is intended for research and analytical applications. Minoxidil (U10858) is an ATP-sensitive potassium (KATP) channel opener, a potent oral antihypertensive agent and a peripheral vasodilator that promotes vasodilation also affects hair growth. Minoxidil is also a potent inhibitor of soybean lipoxygenaseare with an IC50 of 20 μM .
    Minoxidil (Standard)
  • HY-108589
    PNU 37883 hydrochloride

    PNU 37883A

    		 Potassium Channel Neurological Disease
    PNU 37883 hydrochloride (PNU 37883A) is a selective vascular ATP-sensitive potassium (Kir6, KATP) channels blocker. PNU 37883 hydrochloride has diuretic effects with specific binding in kidney and vascular smooth muscle rather than in brain or pancreatic beta cells .
    PNU 37883 hydrochloride
  • HY-113147B
    L-Palmitoylcarnitine TFA
    2 Publications Verification

    		 Endogenous Metabolite Potassium Channel Cardiovascular Disease Metabolic Disease
    L-Palmitoylcarnitine TFA, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine TFA inhibits KATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2 .
    L-Palmitoylcarnitine TFA
  • HY-162322
    VU0542270

    		Potassium Channel Cardiovascular Disease
    VU0542270 is a selective vascular Kir6.1/SUR2B KATP channel inhibitor with an IC50 value of 100 nM. VU0542270 has an IC50 > 30 μM for the other nine members of the Kir channel family. VU0542270 can be used in the study of cardiovascular disease .
    VU0542270
  • HY-23196S
    Minoxidil-d10

    		Potassium Channel Neurological Disease
    Minoxidil-d10 (U10858-d10) is the deuterium labeled Minoxidil. Minoxidil (U10858) is an ATP-sensitive potassium (KATP) channel opener, a potent oral antihypertensive agent and a peripheral vasodilator that promotes vasodilation also affects hair growth. Minoxidil is also a potent inhibitor of soybean lipoxygenaseare with an IC50 of 20 μM[1][2][3].
    Minoxidil-d10
  • HY-106577
    Cibenzoline

    Cifenline; Ro 22-7796

    		 Potassium Channel Cardiovascular Disease Metabolic Disease
    Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a KATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC50 of 22.2 μM. Cibenzoline inhibits IKr and IKs currents with IC50 values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .
    Cibenzoline
  • HY-W017387
    Sodium α-ketoisocaproate
    1 Publications Verification

    Sodium 4-methyl-2-oxopentanoate; 2-Ketoisocaproic acid sodium salt

    		 Branched Chain Amino Acid Transaminase (BCAT) Potassium Channel Na+/Ca2+ Exchanger Metabolic Disease
    Sodium α-ketoisocaproate (Sodium 4-methyl-2-oxopentanoate) is an insulin secretagogue. Sodium α-ketoisocaproate undergoes transamination catalyzed by BCAT and BCATm to produce α-ketoglutarate and leucine; it also binds to the SUR1 site to inhibit KATP channel activity, but does not directly affect the Kir6.2 subunit. Sodium α-ketoisocaproate regulates Ca 2+ influx. Sodium α-ketoisocaproate exerts insulinotropic activity in pancreatic islets and intact mouse pancreata with sufficient BCATm expression. Sodium α-ketoisocaproate can be used in research related to type 2 diabetes .
    Sodium α-ketoisocaproate
  • HY-15208
    Clamikalant sodium

    HMR 1098

    		 Potassium Channel Neurological Disease
    Clamikalant sodium (HMR 1098) is an ATP-sensitive potassium (KATP) channel blocker. Clamikalant sodium can be used for the research of arrhythmia .
    Clamikalant sodium
  • HY-B0254S
    Glipizide-d11

    		Isotope-Labeled Compounds Potassium Channel Metabolic Disease
    Glipizide-d11 is the deuterium labeled Glipizide. Glipizide (CP 2872; K 4024)?a potent, orally active and sulfonylurea class anti-diabetic agent and can be used for type 2?diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium?(KATP) channels among β cells of pancreatic islets of Langerhans .
    Glipizide-d11
  • HY-B0254R
    Glipizide (Standard)

    CP 28720 (Standard); K 4024 (Standard)

    		 Reference Standards Potassium Channel Metabolic Disease
    Glipizide (Standard) is the analytical standard of Glipizide. This product is intended for research and analytical applications. Glipizide (CP 2872; K 4024) a potent, orally active and sulfonylurea class anti-diabetic agent and can be used for type 2 diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium (KATP) channels among β cells of pancreatic islets of Langerhans .
    Glipizide (Standard)
  • HY-167548
    L-α-Phosphatidylinositol-4,5-bisphosphate ammonium

    		PKC Potassium Channel Others
    L-α-Phosphatidylinositol-4,5-bisphosphate ammonium is a key signaling lipid. L-α-Phosphatidylinositol-4,5-bisphosphate ammonium is an activator of PKC in the presence of calcium ions and phospholipid serine. L-α-Phosphatidylinositol-4,5-bisphosphate ammonium is also an antagonist of the KIR3.4 (ATP-sensitive potassium, KATP) channel. L-α-Phosphatidylinositol-4,5-bisphosphate ammonium can be used in research related to signal transduction, ion channel regulation, and membrane transport.
    L-α-Phosphatidylinositol-4,5-bisphosphate ammonium
  • HY-155941
    5-Hydroxydecanoic acid

    		Potassium Channel Neurological Disease
    5-Hydroxydecanoic acid (5-HD） is a KATP channel antagonist，which has the effect of blocking the K KATP channel only during ischaemia by competing with the ATP binding site and does not affect pancreatic KATP channels .
    5-Hydroxydecanoic acid
  • HY-169249
    Aekatperone

    Z1620764636

    		 Potassium Channel Metabolic Disease
    Aekatperone is a reversible KATP channel inhibitor, with an IC50 of 9 μM. Aekatperone can be used for the research of congenital hyperinsulinism (CHI) .
    Aekatperone
  • HY-101069
    Y-26763
    2 Publications Verification

    		 Potassium Channel Cardiovascular Disease
    Y-26763 is a K + channel opener and active metabolite of Y-27152 . Y-26763 is an ATP-sensitive K + (KATP) channel activator .
    Y-26763
  • HY-B0682
    Mitiglinide

    KAD-1229 free acid anhydrous; S21403 free acid anhydrous

    		 Potassium Channel Metabolic Disease
    Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K + (KATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide can be used for the research of type 2 diabetes .
    Mitiglinide
  • HY-17451
    Glibornuride

    		Potassium Channel Metabolic Disease
    Glibornuride is a blocker of ATP-sensitive K + channels (KATP channel) with a pKi of 5.75 . Antidiabetic agent .
    Glibornuride
  • HY-15589R
    GW9508 (Standard)

    		Free Fatty Acid Receptor Potassium Channel Reference Standards Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    GW9508 (Standard) is the analytical standard of GW9508. This product is intended for research and analytical applications. GW9508 is a potent and selective G protein-coupled receptors FFA1 (GPR40) and GPR120 agonist with pEC50s of 7.32 and 5.46, respectively. GW9508 shows ~100-fold selectivity for GPR40 over GPR120. GW9508 is inactive against other GPCRs, kinases, proteases, integrins and PPARs. GW9508 is a glucose-sensitive insulin secretagogue and an ATP-sensitive potassium (KATP) channels opener. Anti-inflammatory and anti-atherosclerotic activities .
    GW9508 (Standard)
  • HY-U00173
    U89232

    		Potassium Channel Cardiovascular Disease
    U-89232 appears to be a cardioselective KATP channel opener.
    U89232
  • HY-19116
    KRN-2391

    		Potassium Channel Neurological Disease Metabolic Disease
    KRN-2391 is a KATP channel opener with NO donor properties. KRN-2391 exerts dual inhibitory effects on overactive bladder (OAB) by activating KATP channels (causing cellular hyperpolarization and bladder smooth muscle relaxation) and releasing NO (enhancing relaxation via cGMP pathways). KRN-2391 is promising for research of OAB .
    KRN-2391
  • HY-W037817
    Dimethyl L-glutamate

    Dimethyl glutamate

    		 Potassium Channel Bacterial Infection Metabolic Disease
    Dimethyl L-glutamate (Dimethyl glutamate), a membrane-permeable analog of Glutamate, can stimulate insulin release induced by Glucose. Dimethyl L-glutamate suppresses the KATP channel activities. Dimethyl L-glutamate inhibits E. gracilis growth and causes abnormal cell division. Dimethyl L-glutamate can be used in the research of diabetes, glucose transport, phosphorylation, and further metabolism .
    Dimethyl L-glutamate
  • HY-115606
    ML077

    		NKCC Endogenous Metabolite Neurological Disease
    ML007 is a selective antagonist targeting the neuron-specific potassium-chloride co-transporter 2 (KCC2) with an IC50 for KCC2 is 537 nM, while its inhibitory activity on KCC1 is extremely weak (IC50 > 50 μM). ML077 inhibits the chloride ion excretion function of KCC2, increasing the intracellular chloride ion concentration, thereby enhancing the depolarization mediated by chloride ion channels. ML007 can promote glucose-stimulated insulin secretion (GSIS) without relying on KATP channels. ML007 can be used to study the functions related to pain, epilepsy, and insulin secretion .
    ML077
  • HY-N0466R
    Rebaudioside A (Standard)

    		Reference Standards Glycosidase HMG-CoA Reductase (HMGCR) Fatty Acid Synthase (FASN) LDLR Others
    Rebaudioside A (Standard) is the analytical standard of Rebaudioside A. This product is intended for research and analytical applications. Rebaudioside A is an orally effective steviol glycoside with high sweetness. Rebaudioside A acts as an inhibitor of α-glucosidase with an IC50 value of 35.01 μg/mL. Rebaudioside A increases the ATP/ADP ratio in β cells in a glucose-dependent manner, thereby inhibiting KATP channels, leading to membrane depolarization, calcium influx, and ultimately stimulating insulin secretion. Rebaudioside A activates the SREBP signaling pathway by inhibiting HMGCR, the rate-limiting enzyme in cholesterol synthesis, resulting in increased expression of LDLR on the cell surface, thus promoting the uptake of LDL-C in the blood. Rebaudioside A can be used for studies on blood glucose and lipid regulation as well as anti-obesity.
    Rebaudioside A (Standard)
  • HY-121183
    Aprikalim

    RP 52891

    		 Potassium Channel Cardiovascular Disease
    Aprikalim (RP 52891), a potassium channel opener (KCO), activates ATP-sensitive K+ (KATP) channels in guinea pig ventricular myocytes. Using patch-clamp techniques, it was found that aprikalim enhances KATP channel activity more effectively in Mg-NDP solution compared to standard solutions. In Mg-NDP solution, aprikalim reduced the sensitivity of KATP channels to ATP, increasing the concentration of ATP required to inhibit channel activity by half (K1) from 56 μM to 180 μM. However, this effect diminished over time. Aprikalim's ability to activate KATP channels in Mg-NDP solution suggests potential therapeutic implications in modulating cardiac excitability and may relate to changes in channel protein enzymatic activity under experimental conditions .
    Aprikalim
  • HY-120158
    ZD0947

    		Potassium Channel Neurological Disease
    ZD0947 is an ATP-sensitive potassium channel activator with relatively effective activation of smooth muscle KATP channels (SUR2B/Kir6.1 and SUR2B/Kir6.2). ZD0947 partially antagonizes pancreatic KATP channels (SUR1/Kir6.2) and cardiac KATP channels (SUR2A/Kir6.2). ZD0947 is potentially used to inhibit overactive bladder (OAB) .
    ZD0947
  • HY-B0682S2
    Mitiglinide-d5 calcium

    		Isotope-Labeled Compounds Potassium Channel Metabolic Disease
    Mitiglinide-d5 (calcium) is deuterium labeled Mitiglinide. Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide can be used for the research of type 2 diabetes .
    Mitiglinide-d5 calcium
  • HY-B0682S1
    (2R)-Mitiglinide-d5 calcium

    		Isotope-Labeled Compounds Potassium Channel Metabolic Disease
    (2R)-Mitiglinide-d5 (calcium) is deuterium labeled Mitiglinide. Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide can be used for the research of type 2 diabetes .
    (2R)-Mitiglinide-d5 calcium
  • HY-17398R
    Mitiglinide calcium (Standard)

    KAD-1229 anhydrous (Standard); S21403 anhydrous (Standard)

    		 Potassium Channel Reference Standards Metabolic Disease
    Mitiglinide (calcium) (Standard) is the analytical standard of Mitiglinide (calcium). This product is intended for research and analytical applications. Mitiglinide Calcium (KAD-1229 anhydrous), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide Calcium is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium can be used for the research of type 2 diabetes .
    Mitiglinide calcium (Standard)
  • HY-B0682AR
    Mitiglinide calcium hydrate (Standard)

    KAD-1229 (Standard); S-21403 (Standard)

    		 Reference Standards Potassium Channel Metabolic Disease
    Mitiglinide (calcium hydrate) (Standard) is the analytical standard of Mitiglinide (calcium hydrate). This product is intended for research and analytical applications. Mitiglinide calcium hydrate (KAD-1229), an insulinotropic agent, is an ATP-sensitive K + (KATP) channel antagonist. Mitiglinide calcium hydrate is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium hydrate can be used for the research of type 2 diabetes .
    Mitiglinide calcium hydrate (Standard)
  • HY-W777434
    Mitiglinide calcium hydrate-d8

    		Isotope-Labeled Compounds Potassium Channel Metabolic Disease
    Mitiglinide (calcium hydrate)-d8 is the deuterium labeled Mitiglinide (calcium hydrate) (HY-B0682A). Mitiglinide calcium hydrate (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide calcium hydrate is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium hydrate can be used for the research of type 2 diabetes .
    Mitiglinide calcium hydrate-d8
  • HY-B0682S
    Mitiglinide-d8 calcium hydrate

    		Potassium Channel Metabolic Disease
    Mitiglinide-d8 calcium hydrate (KAD-1229-d8) is the deuterium labeled Mitiglinide calcium hydrate. Mitiglinide calcium hydrate (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide calcium hydrate is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium hydrate can be used for the research of type 2 diabetes .
    Mitiglinide-d8 calcium hydrate
  • HY-17451R
    Glibornuride (Standard)

    		Reference Standards Potassium Channel Metabolic Disease
    Glibornuride (Standard) is the analytical standard of Glibornuride. This product is intended for research and analytical applications. Glibornuride is a blocker of ATP-sensitive K+ channels (KATP channel) with a pKi of 5.75 . Antidiabetic agent .
    Glibornuride (Standard)
  • HY-119306
    MCC-134

    		Potassium Channel Cardiovascular Disease
    MCC-134, a blocker of mitochondrial and opener of surface ATP-sensitive K+ (KATP) channels, abrogates cardioprotective effects of chronic hypoxia. MCC-134 is a vasorelaxing agent .
    MCC-134
  • HY-114690
    PNU-140975

    BVT.3531

    		 Potassium Channel Neurological Disease
    PNU-140975 (BVT.3531) is a novel and potent bioactive compound. PNU-140975 can reduce body weight and activates KATP channel in isolated arcuate neurons in rats .
    PNU-140975
  • HY-U00201
    KRN4884

    		Potassium Channel Cardiovascular Disease
    KRN4884 is a K + channel opener. In the presence of intracellular ATP (1 mM), KRN4884 (0.1-3 μM) activates KATP channels in a concentration-dependent manner (EC50=0.55 μM).
    KRN4884
  • HY-117283
    rel-Aprikalim

    rel-RP 52891

    		 Potassium Channel Others
    rel-Aprikalim (rel-RP 52891) is the relative configuration of Aprikalim (HY-121183). Aprikalim (RP 52891), a potassium channel opener (KCO), activates ATP-sensitive K + (KATP) channels in guinea pig ventricular myocytes .
    rel-Aprikalim
  • HY-117255
    ZM260384

    		Potassium Channel Others
    ZM260384 is a KATP channel opener that accelerates metabolism and inhibits the decline of guinea pig isolated diaphragm function, thereby affecting muscle contraction. ZM260384 can be used to study muscle function under hypoxic conditions .
    ZM260384
  • HY-14257
    BMS-191095 hydrochloride

    		Potassium Channel Lactate Dehydrogenase Cardiovascular Disease
    BMS-191095 hydrochloride is a mitochondrial KATP channel opener. BMS-191095 hydrochloride can protect the myocardium without causing vasodilation or affecting electrophysiology, by prolonging the contraction time during ischemia, improving contractile function after reperfusion, and reducing lactate dehydrogenase (LDHM) release, thereby exerting its cardioprotective effects .
    BMS-191095 hydrochloride
  • HY-115014
    Cibenzoline succinate

    Cifenline succinate; Ro 22-7796 succinate

    		 Potassium Channel Cardiovascular Disease Metabolic Disease
    Cibenzoline succinate (Cifenline succinate) is the succinate form of Cibenzoline (HY-106577). Cibenzoline succinate is an inhibitor for ATP-sensitive potassium (KATP) channel by affecting the pore-forming Kir6.2 subunit with IC50 of 22.2 µM. Cibenzoline succinate affects insulin secretion and exhibits antiarrhythmic and antidiabetic activities .
    Cibenzoline succinate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: